---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-173928"
form_type: "8-K"
ticker: null
cik: "0001492674"
company_name: "T2 Biosystems, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T17:57:47.974029+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# T2 Biosystems receives Nasdaq bid price deficiency notice; faces potential delisting

## Summary
- Received Nasdaq deficiency letter on June 20, 2023 for bid price below $0.10/share for 10 consecutive days.
- Also previously non-compliant with MVLS minimum $35M; hearing scheduled for July 6, 2023.
- Company plans to present compliance plan to Nasdaq, including potential reverse stock split.
- No assurance of continued listing; delisting risk remains if plan not accepted.

## SEC filing metadata
- accession: 0001193125-23-173928
- form_type: 8-K
- cik: 0001492674
- company_name: T2 Biosystems, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492674/000119312523173928/0001193125-23-173928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492674/000119312523173928/d504829d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-173928
- JSON: https://secwatch.observer/filing/0001193125-23-173928.json
- Plain text: https://secwatch.observer/filing/0001193125-23-173928.txt

## Key facts
- Listing & Compliance Notices
  T2 Biosystems, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5810(c)(3)(A)(iii)
  source text: June 20, 2023, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last ten consecutive business days, the bid price for the Company’s common stock had closed below the minimum $0.10 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stock Rule”). Pursuant to a prior non-compliance letter from Nasdaq dated November 22, 2022, the Company received a letter from Nasdaq indicating that, for the last thirty consecutive business day
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312523173928/0001193125-23-173928-index.htm
- Listing & Compliance Notices
  T2 Biosystems, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: May 23, 2023 to regain compliance with the MVLS. On May 23, 2023 we received a letter from Nasdaq informing us that our shares had failed to comply with the MVLS required for continued listing on The Nasdaq Capital Market and, as a result, our shares are subject to delisting. We filed an appeal and hearing request with Nasdaq requesting an extension of time within which to evidence compliance with all applicable requirements for continued listing, which has stayed the delisting of our common stock from The Nasdaq Capital Market pending a Nasdaq listing qualifications hearings panel’s (the “Pan
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312523173928/0001193125-23-173928-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.